Gleevec

Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By |2018-10-30T09:34:18-04:00September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

Note: The content of this article is current to the time of its posting on February 10, 2016. Please continue to check our site for the latest information on generics. On February 1, 2016, [...]

By |2018-12-17T10:51:32-04:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-04:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Study Indicates Use Of Adjuvant Imatinib Therapy For GIST Increasing

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]

By |2018-09-11T09:21:47-04:00April 7th, 2015|Drug Treatment, Gleevec, News, Survival Strategies|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By |2018-07-06T13:59:34-04:00January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Plasma Level Testing for Imatinib Now Available

Saladax Biomedical, a CLIA certified laboratory based in Bethlehem, Pennsylvania, is now providing plasma level testing for imatinib.(Gleevec). Testing is currently free of charge through January 31, 2015, as it is not covered by [...]

By |2019-04-08T08:46:39-04:00December 15th, 2014|Drug Treatment, Gleevec, News, Patient Support, Plasma Level Testing|

Recent Posts

Upcoming Events

  1. Blueprint Medicines logo

    Informational Webinar on Avapritinib

    August 20 @ 4:00 PM - 5:00 PM
  2. Dr. Sicklick presents an update on Temozolomide Trial